LXJ-02

CAT:
804-HY-P6183
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
LXJ-02 - image 1

LXJ-02

  • Description :

    LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the KD of 117 μM for EDPs. LXJ-02 activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin[1].
  • UNSPSC :

    12352209
  • Target :

    MMP
  • Type :

    Peptides
  • Related Pathways :

    Metabolic Enzyme/Protease
  • Applications :

    Cancer-programmed cell death
  • Field of Research :

    Cancer
  • Assay Protocol :

    https://www.medchemexpress.com/lxj-02.html
  • Solubility :

    10 mM in DMSO
  • Smiles :

    C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N1[C@H](C(N[C@H](C(N)=O)C)=O)CCC1)CO)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)C)=O)CO)(=O)[C@H]2N(C([C@@H](NC(CNC([C@@](NC([C@@H](NC(CCOCCOCCNC(CCOCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)[C@H](C)C)=O)(CC)C)=O)=O)CO)=O)CCC2
  • Molecular Formula :

    C94H159N19O34
  • Molecular Weight :

    2099.37
  • References & Citations :

    [1]Yixiang Wang, et al. Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment. J Med Chem. 2024 Apr 25;67 (8) :6624-6637.
  • Shipping Conditions :

    Room temperature
  • Scientific Category :

    Peptides
  • Clinical Information :

    No Development Reported
  • CAS Number :

    [2672508-37-9]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide